Meeting
2020 Genitourinary Cancers Symposium
MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide.
Authors
Johann S. De Bono
Institute of Cancer Research, Surrey, United Kingdom
Johann S. De Bono , Mark T. Fleming , Judy Sing-Zan Wang , Richard Cathomas , Marna Williams , John G. Bothos , Kemal Balic , Song Hye Cho , Pablo Martinez , Daniel Peter Petrylak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02991911
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 99)
Abstract #
99
Poster Bd #
E1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel Costin Danila
Poster
2021 ASCO Annual Meeting
Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi
Poster
2021 ASCO Annual Meeting
VERU-111, an oral cytoskeleton disruptor, to treat men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.
First Author: Mark Christopher Markowski
Poster
2021 ASCO Annual Meeting
Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study.
First Author: Rahul Raj Aggarwal